[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100391270":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":30,"centralContacts":35,"locations":41,"responsibleParty":79,"collaborators":30,"id":81,"slug":30,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":30,"eligibilityCriteria":86,"healthyVolunteers":82,"sex":87,"minAge":88,"maxAge":30,"enrollmentInfo":89,"targetDuration":30,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":30,"overallStatus":44,"whyStopped":30,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Low dose heparin","ACTIVE_COMPARATOR","heparin (25 IU\u002FKg -maximal dose 3,000 IU)",[13],"Drug: Heparin",{"label":15,"type":10,"description":16,"interventionNames":17},"High dose heparin","heparin 50 IU\u002Fkg -maximal dose 5,000 IU",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Placebo","PLACEBO_COMPARATOR","Normal saline 0.9%.",[23],"Drug: Placebos",[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Heparin","two doses of heparin",[15,9],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Placebos","placebo",[19],[36],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},"Shahar Lavi, MD","CONTACT","519-6633611","Shahar.lavi@lhsc.on.ca",[42,60],{"facility":43,"status":44,"city":45,"state":46,"zip":30,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Hamilton Health Sciences","RECRUITING","Hamilton","Ontario","Canada",{"type":49,"coordinates":50},"Point",[51,52],-79.84963,43.25011,{"lat":52,"lon":51},[55,57],{"name":56,"role":38,"phone":30,"phoneExt":30,"email":30},"Shamir Mehta",{"name":58,"role":59,"phone":30,"phoneExt":30,"email":30},"Shamir Mehta, MD","PRINCIPAL_INVESTIGATOR",{"facility":61,"status":44,"city":62,"state":46,"zip":63,"country":47,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"London Health Sciences Centre","London","N6A5A5",{"type":49,"coordinates":65},[66,67],-81.23304,42.98339,{"lat":67,"lon":66},[70,73,78],{"name":37,"role":38,"phone":71,"phoneExt":30,"email":72},"519-663-3611","shahar.lavi@lhsc.on.ca",{"name":74,"role":38,"phone":75,"phoneExt":76,"email":77},"Cassandra Wagner, MSc","519-685-8500","35625","cassandra.wagner@lhsc.on.ca",{"name":37,"role":59,"phone":30,"phoneExt":30,"email":30},{"type":80,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100391270",false,"NCT04374799","Heparin vs Placebo for Cardiac Catheterization","A Randomized Trial of Heparin vs Placebo in Patients Undergoing Cardiac Catheterization Via the Trans-radial Approach","Inclusion Criteria:\n\n* diagnostic cardiac catheterization; Small size sheath; patency of the ulno-palmar circulation\n\nExclusion Criteria:\n\nabnormal ulno-palmar circulation; Prior radial artery thrombosis; Prior surgery close to the access site; Emergent cardiac catheterization; History of HIT or allergy to heparin; Patients requiring anticoagulation","ALL","18 Years",{"count":90,"type":91},1623,"ESTIMATED","INTERVENTIONAL",[94],"PHASE3","Patients undergoing cardiac catheterization will be randomized to 3 groups: no anticoagulant, low dose anticoagulant and high dose anticoagulant.",[97],"Cardiac Disease","2026-02-18",{"date":100,"type":101},"2026-02-20","ACTUAL",{"date":103,"type":101},"2020-10-05",{"date":105,"type":91},"2026-12",{"name":5,"class":6},2]